# Butterfly Network, Inc.: financial statements, quarterly

BFLY · NYSE · CIK 1804176 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bfly.md) · [Financials](/companies/bfly/financials.md) · [Filings](/companies/bfly/filings.md) · [Insiders](/companies/bfly/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bfly/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [16.5 d](/filings/0001804176-26-000009.md) | [17.7](/filings/0001628280-25-021669.md) | [21.5](/filings/0001628280-25-037249.md) | [20.6](/filings/0001804176-25-000009.md) | [22.4 d](/filings/0001804176-26-000009.md) | [21.2](/filings/0001804176-26-000016.md) | [23.4](/filings/0001804176-26-000027.md) | [21.5](/filings/0001804176-26-000040.md) | [31.5 d](/filings/0001804176-26-000009.md) | [26.5](/filings/0001804176-26-000016.md) | [32.6](/filings/0001804176-26-000027.md) | [32.6](/filings/0001804176-26-000040.md) |
| Cost of revenue | $m | [29.1 d](/filings/0001628280-25-009036.md) | [7.4](/filings/0001558370-24-006395.md) | [8.9](/filings/0001558370-24-010607.md) | [8.3](/filings/0001558370-24-014082.md) | [8.6 d](/filings/0001628280-25-009036.md) | [7.8](/filings/0001804176-26-000016.md) | [8.5](/filings/0001804176-26-000027.md) | [25.2](/filings/0001804176-26-000040.md) | [10.3 d](/filings/0001804176-26-000009.md) | [8.2](/filings/0001804176-26-000016.md) | [9.3](/filings/0001804176-26-000027.md) | [8.8](/filings/0001804176-26-000040.md) |
| Gross profit | $m | [(12.5) d](/filings/0001804176-26-000009.md) | [10.3](/filings/0001628280-25-021669.md) | [12.6](/filings/0001628280-25-037249.md) | [12.2](/filings/0001804176-25-000009.md) | [13.7 d](/filings/0001804176-26-000009.md) | [13.4](/filings/0001804176-26-000016.md) | [14.9](/filings/0001804176-26-000027.md) | [(3.8)](/filings/0001804176-26-000040.md) | [21.2 d](/filings/0001804176-26-000009.md) | [18.3](/filings/0001804176-26-000016.md) | [23.3](/filings/0001804176-26-000027.md) | [23.8](/filings/0001804176-26-000040.md) |
| Research and development | $m | [11.2 d](/filings/0001804176-26-000009.md) | [10.7](/filings/0001628280-25-021669.md) | [9.4](/filings/0001628280-25-037249.md) | [8.8](/filings/0001804176-25-000009.md) | [8.8 d](/filings/0001804176-26-000009.md) | [9.9](/filings/0001804176-26-000016.md) | [8.3](/filings/0001804176-26-000027.md) | [8.7](/filings/0001804176-26-000040.md) | [9.3 d](/filings/0001804176-26-000009.md) | [9.5](/filings/0001804176-26-000016.md) | [10.5](/filings/0001804176-26-000027.md) | [10.2](/filings/0001804176-26-000040.md) |
| Operating income | $m | [(46.7) d](/filings/0001804176-26-000009.md) | [(22.6)](/filings/0001628280-25-021669.md) | [(17.2)](/filings/0001628280-25-037249.md) | [(17.2)](/filings/0001804176-25-000009.md) | [(17.3) d](/filings/0001804176-26-000009.md) | [(18.5)](/filings/0001804176-26-000016.md) | [(16.1)](/filings/0001804176-26-000027.md) | [(35.1)](/filings/0001804176-26-000040.md) | [(16.7) d](/filings/0001804176-26-000009.md) | [(13.9)](/filings/0001804176-26-000016.md) | [(13.7)](/filings/0001804176-26-000027.md) | [(13.6)](/filings/0001804176-26-000040.md) |
| Interest expense | $m | not reported | [0.3](/filings/0001558370-24-006395.md) | [0.3](/filings/0001628280-25-037249.md) | [0.3](/filings/0001804176-25-000009.md) | [0.3 d](/filings/0001804176-26-000009.md) | [0.3](/filings/0001804176-26-000016.md) | [0.4](/filings/0001804176-26-000027.md) | [0.4](/filings/0001804176-26-000040.md) | [0.4 d](/filings/0001804176-26-000009.md) | [0.3](/filings/0001804176-26-000016.md) | [0.3](/filings/0001804176-26-000027.md) | [0.3](/filings/0001804176-26-000040.md) |
| Income tax | $m | [0.0 d](/filings/0001804176-26-000009.md) | [0.0](/filings/0001628280-25-021669.md) | [0.0](/filings/0001628280-25-037249.md) | [0.1](/filings/0001804176-25-000009.md) | [(0.1) d](/filings/0001804176-26-000009.md) | [0.0](/filings/0001804176-26-000016.md) | [0.0](/filings/0001804176-26-000027.md) | [0.0](/filings/0001804176-26-000040.md) | [0.1 d](/filings/0001804176-26-000009.md) | [0.0](/filings/0001804176-26-000016.md) | [0.0](/filings/0001804176-26-000027.md) | [0.0](/filings/0001804176-26-000040.md) |
| Net income | $m | [(44.1) d](/filings/0001804176-26-000009.md) | [(21.8)](/filings/0001628280-25-021669.md) | [(15.7)](/filings/0001628280-25-037249.md) | [(16.9)](/filings/0001804176-25-000009.md) | [(18.1) d](/filings/0001804176-26-000009.md) | [(14.0)](/filings/0001804176-26-000016.md) | [(13.8)](/filings/0001804176-26-000027.md) | [(34.0)](/filings/0001804176-26-000040.md) | [(15.3) d](/filings/0001804176-26-000009.md) | [(12.7)](/filings/0001804176-26-000016.md) | [(12.9)](/filings/0001804176-26-000027.md) | [(12.8)](/filings/0001804176-26-000040.md) |
| Diluted EPS | $ per share | not reported | [(0.10)](/filings/0001628280-25-021669.md) | [(0.07)](/filings/0001628280-25-037249.md) | [(0.08)](/filings/0001804176-25-000009.md) | not reported | [(0.06)](/filings/0001804176-26-000016.md) | [(0.06)](/filings/0001804176-26-000027.md) | [(0.13)](/filings/0001804176-26-000040.md) | not reported | [(0.05)](/filings/0001804176-26-000016.md) | [(0.05)](/filings/0001804176-26-000027.md) | [(0.05)](/filings/0001804176-26-000040.md) |
| Basic EPS | $ per share | not reported | [(0.10)](/filings/0001628280-25-021669.md) | [(0.07)](/filings/0001628280-25-037249.md) | [(0.08)](/filings/0001804176-25-000009.md) | not reported | [(0.06)](/filings/0001804176-26-000016.md) | [(0.06)](/filings/0001804176-26-000027.md) | [(0.13)](/filings/0001804176-26-000040.md) | not reported | [(0.05)](/filings/0001804176-26-000016.md) | [(0.05)](/filings/0001804176-26-000027.md) | [(0.05)](/filings/0001804176-26-000040.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [134](/filings/0001628280-25-009036.md) | [113](/filings/0001628280-25-021669.md) | [102](/filings/0001628280-25-037249.md) | [93.8](/filings/0001804176-25-000009.md) | [88.8](/filings/0001804176-26-000009.md) | [155](/filings/0001804176-26-000016.md) | [148](/filings/0001804176-26-000027.md) | [144](/filings/0001804176-26-000040.md) | [150](/filings/0001804176-26-000040.md) | [138](/filings/0001804176-26-000016.md) | [125](/filings/0001804176-26-000027.md) | [122](/filings/0001804176-26-000040.md) |
| Current assets | $m | [231](/filings/0001628280-25-009036.md) | [213](/filings/0001558370-24-006395.md) | [204](/filings/0001558370-24-010607.md) | [199](/filings/0001558370-24-014082.md) | [193](/filings/0001804176-26-000009.md) | [257](/filings/0001628280-25-021669.md) | [254](/filings/0001628280-25-037249.md) | [241](/filings/0001804176-25-000009.md) | [249](/filings/0001804176-26-000040.md) | [240](/filings/0001804176-26-000016.md) | [238](/filings/0001804176-26-000027.md) | [244](/filings/0001804176-26-000040.md) |
| Total assets | $m | [304](/filings/0001628280-25-009036.md) | [284](/filings/0001558370-24-006395.md) | [273](/filings/0001558370-24-010607.md) | [265](/filings/0001558370-24-014082.md) | [256](/filings/0001804176-26-000009.md) | [318](/filings/0001628280-25-021669.md) | [313](/filings/0001628280-25-037249.md) | [290](/filings/0001804176-25-000009.md) | [297](/filings/0001804176-26-000040.md) | [286](/filings/0001804176-26-000016.md) | [283](/filings/0001804176-26-000027.md) | [288](/filings/0001804176-26-000040.md) |
| Current liabilities | $m | [44.3](/filings/0001628280-25-009036.md) | [41.5](/filings/0001558370-24-006395.md) | [40.8](/filings/0001558370-24-010607.md) | [42.8](/filings/0001558370-24-014082.md) | [48.2](/filings/0001804176-26-000009.md) | [42.5](/filings/0001628280-25-021669.md) | [44.7](/filings/0001628280-25-037249.md) | [50.3](/filings/0001804176-25-000009.md) | [65.1](/filings/0001804176-26-000040.md) | [59.6](/filings/0001804176-26-000016.md) | [58.6](/filings/0001804176-26-000027.md) | [68.0](/filings/0001804176-26-000040.md) |
| Total liabilities | $m | [84.2](/filings/0001628280-25-009036.md) | [80.3](/filings/0001558370-24-006395.md) | [78.8](/filings/0001558370-24-010607.md) | [83.4](/filings/0001558370-24-014082.md) | [87.3](/filings/0001804176-26-000009.md) | [78.7](/filings/0001628280-25-021669.md) | [80.5](/filings/0001628280-25-037249.md) | [86.2](/filings/0001804176-25-000009.md) | [101](/filings/0001804176-26-000040.md) | [94.7](/filings/0001804176-26-000016.md) | [93.6](/filings/0001804176-26-000027.md) | [104](/filings/0001804176-26-000040.md) |
| Shareholders' equity | $m | [220](/filings/0001804176-26-000009.md) | [204](/filings/0001628280-25-037249.md) | [194](/filings/0001804176-25-000009.md) | [182](/filings/0001804176-25-000009.md) | [169](/filings/0001804176-26-000040.md) | [240](/filings/0001804176-26-000027.md) | [233](/filings/0001804176-26-000040.md) | [204](/filings/0001804176-26-000040.md) | [196](/filings/0001804176-26-000040.md) | [191](/filings/0001804176-26-000027.md) | [189](/filings/0001804176-26-000040.md) | [184](/filings/0001804176-26-000040.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.1) d](/filings/0001804176-26-000009.md) | [(20.7)](/filings/0001628280-25-021669.md) | [(10.0) d](/filings/0001628280-25-037249.md) | [(7.9) d](/filings/0001804176-25-000009.md) | [(3.1) d](/filings/0001804176-26-000009.md) | [(11.7)](/filings/0001804176-26-000016.md) | [(7.2) d](/filings/0001804176-26-000027.md) | [(2.9) d](/filings/0001804176-26-000040.md) | [9.0 d](/filings/0001804176-26-000009.md) | [(13.9)](/filings/0001804176-26-000016.md) | [(16.3) d](/filings/0001804176-26-000027.md) | [(2.3) d](/filings/0001804176-26-000040.md) |
| Capital expenditure | $m | [2.5 d](/filings/0001804176-26-000009.md) | [1.1](/filings/0001628280-25-021669.md) | [0.7 d](/filings/0001628280-25-037249.md) | [0.4 d](/filings/0001804176-25-000009.md) | [0.4 d](/filings/0001804176-26-000009.md) | [0.4](/filings/0001804176-26-000016.md) | [0.9 d](/filings/0001804176-26-000027.md) | [1.0 d](/filings/0001804176-26-000040.md) | [1.1 d](/filings/0001804176-26-000009.md) | [1.0](/filings/0001804176-26-000016.md) | [1.0 d](/filings/0001804176-26-000027.md) | [1.1 d](/filings/0001804176-26-000040.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [203](/filings/0001558370-24-006395.md) | [205](/filings/0001558370-24-010607.md) | [207](/filings/0001558370-24-014082.md) | [209](/filings/0001628280-25-021669.md) | [212](/filings/0001628280-25-037249.md) | [213](/filings/0001804176-25-000009.md) | [235](/filings/0001804176-26-000016.md) | [248](/filings/0001804176-26-000027.md) | [252](/filings/0001804176-26-000040.md) | [257](/filings/0001804176-26-000016.md) | [262](/filings/0001804176-26-000027.md) | [266](/filings/0001804176-26-000040.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 07:34 ET. No prices; not investment advice.